RANDI2 is an open source web application for randomization within clinical trials. It supports a variety of randomization algorithms and offers a very useful set of functions for randomization data & progress visualization and trial management - for more information please visit http://www.randi2.org
You can use the category filters given on the right sidebar to narrow down your search results.
MassChroQ (Mass Chromatogram Quantification) software performs quantification of data obtained from mass-spectrometry techniques. It is particularly well suited for peptide quantification of LC-MS (Liquid Chromatography - Mass Spectrometry) data. It performs chromatographic alignment, XIC extraction, peak detection and quantification on identified peptides, with or without isotopic labeling, on high or low resolution data and it takes into account peptide or protein fractionation.
Bioconductor is an open source, open development software project to provide tools for the analysis and comprehension of high-throughput genomic data. It is based primarily on the R programming language.
The Bioconductor release version is updated twice each year, and is appropriate for most users. There is also a development version, to which new features and packages are added prior to incorporation in the release. A large number of meta-data packages provide pathway, organism, microarray and other annotations.
i2b2 has turned out to be a very valuable component for secondary use of routine clinical data. Its pragmatic database schema allows merging of data from heterogeneous data sources, and the intuitive user interface enables easy querying and powerful processing. However, it's a component rather than a complete solution: The user is facing several barriers when integrating i2b2 into the operational workflow.
i2b2 (Informatics for Integrating Biology and the Bedside) is an NIH-funded National Center for Biomedical Computing based at Partners HealthCare System. The i2b2 Center is developing a scalable informatics framework that will enable clinical researchers to use existing clinical data for discovery research and, when combined with IRB-approved genomic data, facilitate the design of targeted therapies for individual patients with diseases having genetic origins. This platform currently enjoys wide international adoption by the CTSA network, academic health centers, and industry.